Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  09:53 2022-08-08 am EDT
201.14 USD   +3.43%
07:17aBEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
07:09aNomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
06:08aNomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Beigene

06/22/2022 | 05:56pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BEIGENE, LTD.
07:17aBEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
07:09aNomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
06:08aNomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05ANALYST RECOMMENDATIONS : Eli Lilly, KLA, Kellogg, Epam Systems, BeiGene...
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
08/04BEIGENE : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/04Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $341.6M
MT
08/04BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 393 M - -
Net income 2022 -1 594 M - -
Net cash 2022 2 960 M - -
P/E ratio 2022 -14,6x
Yield 2022 -
Capitalization 20 122 M 20 122 M -
EV / Sales 2022 12,3x
EV / Sales 2023 8,79x
Nbr of Employees 8 500
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 194,47 $
Average target price 280,24 $
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-28.22%20 122
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093